Prophylactic Effect ofMycobacterium bovisBCG Vaccination against Osteomyelitis in Children withMycobacterium ulceransDisease (Buruli Ulcer)
Open Access
- 1 November 2002
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 9 (6), 103-107
- https://doi.org/10.1128/cdli.9.6.1389-1391.2002
Abstract
Mycobacterium ulceransdisease, or Buruli ulcer (BU), causes significant morbidity in West Africa. In 233 consecutive, laboratory-confirmed samples from BU patients in Benin whoseMycobacterium bovisBCG scar status was known, 130 children (M. ulceransosteomyelitis in children with BU disease.Keywords
This publication has 19 references indexed in Scilit:
- Protective Efficacy of a DNA Vaccine Encoding Antigen 85A from Mycobacterium bovis BCG against Buruli UlcerInfection and Immunity, 2001
- Immune Response to Infection withMycobacterium ulceransInfection and Immunity, 2001
- Insects in the transmission of Mycobacterium ulcerans infectionThe Lancet, 1999
- Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in MalawiThe Lancet, 1996
- Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in TogoBritish Journal of Dermatology, 1996
- Mycobacterial Infections of the SkinPublished by Springer Nature ,1995
- Immunosuppressive Properties of the Soluble Toxin from Mycobacterium ulceransThe Journal of Infectious Diseases, 1988
- The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of UgandaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1976
- The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infectionEpidemiology and Infection, 1975
- B.C.G. VACCINATION AGAINST MYCOBACTERIUM ULCERANS INFECTION (BURULI ULCER): First Results of a Trial in UgandaThe Lancet, 1969